We invest in the core science needed to demonstrate that new products are in fact less harmful than cigarettes. We have recruited scientists from around the world, from many different disciplines, who share the common goal of tobacco harm reduction.
We have a team of more than 400 scientists, physicians, product developers, engineers, regulatory experts and others who are dedicated to developing innovative products, pursuing their regulatory authorization and constructively engaging with the FDA on policy. Much of this work occurs at our Center for Research and Technology (CRT) in Richmond, Virginia.
To support our scientific efforts, we established a rigorous scientific framework based on the FDA's guidance to evaluate potentially reduced-harm tobacco products.
Our scientific approach focuses on:
- measuring harmful and potentially harmful compounds;
- evaluating the product's health effects;
- researching how adult tobacco consumers use the product and their understanding of its risk; and
- substantiating that the product is unlikely to appeal to unintended audiences.
We share the results of our scientific studies with the FDA and others through peer-reviewed journals, conference presentations, one-on-one meetings.